Multifunctional scaffolds that combine structural support with the controlled delivery of bioactive agents remain a major challenge in tissue engineering. To extend the use of these devices in biomedicine, 3D printing is presented as an alternative that enables the manufacture of complex devices tailored to each patient, thereby solving specific problems in a timely and efficient manner. In this study, porous 3D scaffolds were fabricated via digital light processing (DLP) using a PET-RAFT resin composed of 2-(dimethylamino)ethyl methacrylate (DMAEMA) and poly(ethylene glycol) diacrylate (PEGDA575). Sodium chloride (NaCl) was incorporated as a porogen, while insulin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles were embedded as osteoinductive agents. The printed constructs exhibited high-resolution, reproducible trabecular-like architectures, as confirmed by micro-computed tomography (micro-CT), with interconnected pores averaging 70.7 ± 24.7 μm and a total porosity of 57.0 ± 6.98%. Thermal and chemical analyses confirmed scaffold stability and controlled degradability. Cytocompatibility assays using MC3T3-E1, C2C12, hGMSCs, and C166-GFP cells showed viability above 80% after 7 days (ISO 10993-5). Insulin-loaded nanoparticles enabled sustained release, characterized by an initial burst followed by gradual release up to 72 h. Dynamic bioreactor culture enhanced cell adhesion and RUNX2 expression, confirming the osteoinductive potential of the hybrid scaffold for advanced BTE applications. This study introduces an innovative PET-RAFT-derived resin that combines structural reinforcement with spatiotemporal regulation of insulin release, offering a potential strategy for enhanced biomaterial tissue engineering and tailored therapeutic interventions.
Rodríguez-Umanzor et al. (Tue,) studied this question.